Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy
Univ Klin Innsbruck, Innsbruck, Austria..
Rehabil Zentrum Grossgmain, Salzburg, Austria..
Klinikum Dortmund Mitte, Dortmund, Germany..
HM Broggi, Barcelona, Spain..
Show others and affiliations
2017 (English)In: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 243, p. 389-395Article in journal (Refereed) Published
Abstract [en]

Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hospitalizations. Heart transplantation and left ventricular assist device implantation are viable options only for a minority, and intermittent or continuous infusions of positive inotropes may be needed as a bridge therapy or as a symptomatic approach. In these settings, levosimendan has potential advantages over conventional inotropes (catecholamines and phosphodiesterase inhibitors), such as sustained effects after initial infusion, synergy with beta-blockers, and no increase in oxygen consumption. Levosimendan has been suggested as a treatment that reduces re-hospitalization and improves quality of life. However, previous clinical studies of intermittent infusions of levosimendan were not powered to show statistical significance on key outcome parameters. A panel of 45 expert clinicians from 12 European countries met in Rome on November 24-25, 2016 to review the literature and envision an appropriately designed clinical trial addressing these needs. In the earlier FIGHT trial (daily subcutaneous injection of liraglutide in heart failure patients with reduced ejection fraction) a composite Global Rank Score was used as primary end-point where death, re-hospitalization, and change in N-terminalprohormone-brain natriuretic peptide level were considered in a hierarchical order. In the present study, we tested the same end-point post hoc in the PERSIST and LEVOREP trials on oral and repeated i.v. levosimendan, respectively, and demonstrated superiority of levosimendan treatment vs placebo. The use of the same composite end-point in a properly powered study on repetitive levosimendan in advanced heart failure is strongly advocated.

Place, publisher, year, edition, pages
2017. Vol. 243, p. 389-395
Keywords [en]
Advanced heart failure, Levosimendan, Intermittent, Repetitive, Clinical trial, Composite end-point
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:uu:diva-333061DOI: 10.1016/j.ijcard.2017.05.081ISI: 000406038100076PubMedID: 28571618OAI: oai:DiVA.org:uu-333061DiVA, id: diva2:1155987
Available from: 2017-11-10 Created: 2017-11-10 Last updated: 2017-11-10Bibliographically approved

Open Access in DiVA

fulltext(346 kB)29 downloads
File information
File name FULLTEXT01.pdfFile size 346 kBChecksum SHA-512
b5a780dad16f0fc2af6f8d620a0d717a75243998b65191ffc39ed58f9e4f62e55eb4a1096574e632e4e0809644c8f21c26d0af9424ec779678b937c04fb429a1
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wikström, Gerhard
By organisation
Cardiology
In the same journal
International Journal of Cardiology
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
Total: 29 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 123 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf